Protein Structures available for Human Coagulation Factor VII
All structural analysis of the mutations presented within this database uses the (2A2Q) that was taken from the Protein Data Bank. Structure 2A2Q consists of active site-inhibited FVIIa in complex with soluble Tissue Factor (Bajaj et al., 2006, PMID: 16757484).
| PDB | Description | In Complex with | Resolution | Chain | Position | PDBSum |
|---|---|---|---|---|---|---|
| 1BF9 | N-terminal EGF-like domain from human Factor VII | - | A |
105-145 |
>> | |
| 1CVW | Crystal structure of active site-inhibited human coagulation Factor VIIa (des-Gla) | 2.2 | H L |
213-466 150-204 |
>> | |
| 1DAN | Complex of active site inhibited human blood coagulation Factor VIIa with human recombinant soluble Tissue Factor | TF | 2 | H L |
213-466 61-212 |
>> |
| 1DVA | Crystal structure of the complex between the peptide exosite inhibitor e-76 and coagulation Factor VIIa | exosite peptide | 3 | H/I L/M |
213-466 102-202 |
>> |
| 1F7E | The first EGF-like domain from human blood coagulation FVII | - | A |
105-147 |
>> | |
| 1F7M | The first EGF-like domain from human blood coagulation FVII | - | A |
105-147 |
>> | |
| 1FAK | Human Tissue Factor complexed with coagulation Factor VIIa inhibited with a bpti-mutant | TF | 2.1 | H L |
213-466 61-212 |
>> |
| 1FF7 | The first EGF-like domain from human blood coagulation FVII (fucosylated at ser-60) | - | A |
105-147 |
>> | |
| 1FFM | The first EGF-like domain from human blood coagulation FVII (fucosylated at ser-60) | - | A |
105-147 |
>> | |
| 1J9C | Crystal structure of Tissue Factor-Factor VIIa complex | TF | 2.9 | H L |
213-466 108-202 |
>> |
| 1JBU | Coagulation Factor VII zymogen (EGF2/protease) in complex with inhibitory exosite peptide a-183 | exosite peptide | 2 | H L |
213-466 150-212 |
>> |
| 1KLI | CoFactor-and substrate-assisted activation of Factor VIIa | 1.6 | H L |
213-466 144-212 |
>> | |
| 1KLJ | Crystal structure of uninhibited Factor VIIa | 2.4 | H L |
213-466 144-212 |
>> | |
| 1NL8 | Theoretical model of the Tissue Factor/Factor VIIa/Factor xa complex | TF | - | H M |
213-466 61-202 |
>> |
| 1O5D | Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) | 2 | H L |
213-466 61-212 |
>> | |
| 1QFK | Structure of human Factor VIIa and its implications for the triggering of blood coagulation | 2.8 | H L |
213-466 109-212 |
>> | |
| 1W0Y | TF7a_3771 complex - design of selective phenylglycine amide Tissue Factor/Factor VIIa inhibitors | TF | 2.5 | H L |
213-466 61-202 |
>> |
| 1W2K | TF7a_4380 complex - design of selective phenylglycine amide Tissue Factor/Factor VIIa inhibitors | TF | 3 | H L |
213-466 61-202 |
>> |
| 1W7X | Selective and orally bioavailable phenylglycine Tissue Factor/Factor VIIa inhibitors | TF | 1.8 | H L |
213-466 150-204 |
>> |
| 1W8B | Selective and orally bioavailable phenylglycine Tissue Factor/Factor VIIa inhibitors | TF | 3 | H L |
213-466 148-204 |
>> |
| 1WQV | Crystal structure of human Factor VIIa/Tissue Factor in complex with peptide mimetic inhibitor | TF | 2.5 | H L |
213-466 61-212 |
>> |
| 1WSS | Human Factor VIIa-Tissue Factor in complex with peprid mimetic inhibitor that has two charge groups in p2 and p4 | TF | 2.6 | H L |
213-466 61-212 |
>> |
| 1WTG | Human Factor VIIa-Tissue Factor complexed with ethylsulfonamide-d-biphenylalanine-gln-p-aminobenzamidine | TF | 2.2 | H L |
213-466 61-212 |
>> |
| 1WUN | Human Factor VIIa-Tissue Factor complexed with ethylsulfonamide-d-trp-gln-p-aminobenzamidine | TF | 2.4 | H L |
213-466 61-212 |
>> |
| 1WV7 | Human Factor VIIa-Tissue Factor complexed with ethylsulfonamide-d-5-propoxy-trp-gln-p-aminobenzamidine | TF | 2.7 | H L |
213-466 61-212 |
>> |
| 1YGC | Short Factor VIIa with a small molecule inhibitor | 2 | H L |
213-466 150-212 |
>> | |
| 1Z6J | Crystal structure of a ternary complex of Factor VIIa/Tissue Factor/pyrazinone inhibitor | TF | 2 | H L |
213-466 61-202 |
>> |
| 2A2Q | Complex of Active-site Inhibited Human Coagulation Factor VIIa with Human Soluble Tissue Factor | TF | 1.8 | H L |
213-466 61-212 |
>> |
| 2AEI | The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex | TF | 2.5 | H L |
213-466 61-212 |
>> |
| 2AER | Crystal structure of benzamidine-Factor VIIa/soluble Tissue Factor complex | TF | 1.8 | H L |
213-466 61-202 |
>> |
| 2B7D | Factor VIIa-Tissue Factor (FVIIa.TF) complex inhibitors | TF | 2.2 | H L |
213-466 61-212 |
>> |
| 2B8O | Crystal structure of glu-gly-arg-chloromethyl ketone-Factor VIIa/soluble Tissue Factor complex | TF | 2.8 | H L |
213-466 61-202 |
>> |
| 2BZ6 | Orally available Factor7a inhibitor | 1.6 | H L |
213-466 150-202 |
>> | |
| 2C4F | The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex | TF | 1.7 | H L |
213-466 61-202 |
>> |
| 2EC9 | Crystal structure analysis of human Factor VIIa | 2 | H L |
213-466 61-202 |
>> | |
| 2F9B | Discovery of novel heterocyclic Factor VIIa inhibitors | 2.5 | H L |
213-466 61-212 |
>> | |
| 2FIR | Crystal structure of dfpr-VIIa/sTF | TF | 2 | H L |
213-466 61-202 |
>> |
| 2FLB | Novel 5-azaindole Factor VIIa inhibitors | 1.9 | H L |
213-466 61-212 |
>> | |
| 2FLR | Human Factor VIIa-Tissue Factor complexed with benzylsulfonamide-d-ile-gln-p-aminobenzamidine | TF | 2.3 | H L |
213-466 61-212 |
>> |
| 2PUQ | Human Factor VIIa-Tissue Factor complexed with highly selective peptide inhibitor | TF | 2 | H L |
213-466 109-202 |
>> |
| 2ZP0 | Human Factor VIIa-Tissue Factor complexed with benzylsulfonamide-d-ile-gln-p-aminobenzamidine | TF | 2.7 | H L |
213-466 61-212 |
>> |
| 2ZWL | Human Factor VIIa-Tissue Factor complexed with highly selective peptide inhibitor | TF | 2.2 | H L |
213-466 61-212 |
>> |
| 2ZZU | Design and synthesis of peptidomimetic Factor VIIa inhibitors | 2.5 | H L |
213-466 61-212 |
>> | |
| 3ELA | Crystal structure of active site inhibited coagulation Factor VIIa mutant in complex with soluble Tissue Factor | TF | 2.2 | H L |
213-466 61-212 |
>> |
| 3TH2 | Gamma-carboxyglutamic acid (Gla) domains of vitamin k-dependent clotting Factors at physiological Ca2+ | 1.7 | H L |
213-466 61-202 |
>> | |
| 3TH3 | Gamma-carboxyglutamic acid (Gla) domains of vitamin k-dependent clotting Factors at physiological Ca2+ | 2.7 | H L |
213-466 61-202 |
>> | |
| 3TH4 | Gamma-carboxyglutamic acid (Gla) domains of vitamin k-dependent clotting Factors at physiological Ca2+ | 1.8 | H L |
213-466 61-202 |
>> | |
| 4IBL | Rubidium Sites in Blood Coagulation Factor VIIa in complex with Tissue Factor | TF | 1.8 | H L |
213-466 61-212 |
>> |
| 4ISH | Structure of FACTOR VIIA in complex with the inhibitor BMS-593214, a potent, selective FVIIa inhibitor | hydrolase inhibitor | 1.8 | H L |
213-416 150-204 |
>> |
| 4ISI | Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors | TF | 1.9 | H L |
213-466 150-204 |
>> |
| 4JYU | Nonbenzamidine acylsulfonamide Tissue Factor-Factor VIIa inhibitors | TF | 1.8 | H L |
213-466 150-204 |
>> |
| 4JYV | Nonbenzamidine acylsulfonamide Tissue Factor-Factor VIIa inhibitors | TF | 2.1 | H L |
213-466 150-204 |
>> |
| 4JZD | Nonbenzamidine acylsulfonamide Tissue Factor-Factor VIIa inhibitors | TF | 2.2 | H L |
213-466 150-204 |
>> |
| 4JZE | Discovery of nonbenzamidine Factor VIIa inhibitors using a biaryl acid scaffold | 1.5 | H L |
213-466 150-204 |
>> | |
| 4JZF | Discovery of nonbenzamidine Factor VIIa inhibitors using a biaryl acid scaffold | 1.8 | H L |
213-466 150-204 |
>> | |
| 4NA9 | Tetrahydroquinoline derivatives as potent and selective Factor XIa inhibitors | 2.2 | H L |
213-466 150-204 |
>> | |
| 4NG9 | Design and synthesis of phenylpyrrolidine phenylglycinamides as highly potent and selective TF-FVIIa inhibitors | TF | 2.2 | H L |
213-466 150-204 |
>> |
| 4NGA | Design and synthesis of phenylpyrrolidine phenylglycinamides as highly potent and selective TF-FVIIa inhibitors | TF | 2.1 | H L |
213-466 150-204 |
>> |
| 4X8S | Factor VIIa in complex with the inhibitor 4-bromo-2-methoxyphenol | hydrolase inhibitor | 2.1 | H L |
213-466 150-204 |
>> |
| 4X8T | Factor VIIa in complex with the inhibitor 3Z8 | hydrolase inhibitor | 2.2 | H L |
213-466 150-204 |
>> |
| 4X8U | Factor VIIa in complex with the inhibitor 3ZB | hydrolase inhibitor | 2.1 | H L |
213-466 150-204 |
>> |
| 4X8V | Discovery of Novel P1 Groups for Coagulation Factor VIIa Inhibition Using Fragment-Based Screening. | hydrolase inhibitor | 2.5 | H L |
213-466 150-204 |
>> |
| 4YT6 | Factor VIIa in complex with the inhibitor 4JY | hydrolase inhibitor | 2.0 | H L |
213-466 148-204 |
>> |
| 4YT7 | Factor VIIa in complex with the inhibitor 4K1 | hydrolase inhibitor | 2.3 | H L |
213-466 148-204 |
>> |
| 4ZXX | Factor VIIa in complex with 4T0 Inhibitor | hydrolase inhibitor | 2.6 | H L |
213-466 150-204 |
>> |
| 4ZXY | Factor VIIa in complex with 4T1 Inhibitor | hydrolase inhibitor | 2.0 | H L |
213-466 150-204 |
>> |